降脂通络软胶囊治疗原发性高脂血症的预算影响分析  

Analysis on the Budget Influence of Jiangzhi Tongluo Soft Capsules in the Treatment of Primary Hyperlipidemia

作　　者：张梦培 卢斯琪 王晓梅 王葳 周佳孟 左凯妮 潘婕 朱文涛[1] Zhang Mengpei;Lu Siqi;Wang Xiaomei;Wang Wei;Zhou Jiameng;Zuo Kaini;Pan Jie;Zhu Wentao(Collage of Administration,Beijing University of Chinese Medicine,Bejing 100029,China)

机构地区：[1]北京中医药大学管理学院,北京100029

出　　处：《中国药师》2022年第9期1610-1615,共6页China Pharmacist

摘　　要：目的:评估降脂通络软胶囊纳入《国家基本医疗保险、工伤保险和生育保险药品目录》(以下简称“药品目录”)报销对医保基金支出可能产生的影响。方法:基于国际药物经济学与结果研究协会公布的预算影响分析《预算影响分析指南》,采用Excel软件构建降脂通络软胶囊治疗原发性高脂血症的预算影响分析模型,模型模拟时间范围设定为5年(2021~2025年),对降脂通络软胶囊纳入药品目录报销对医保基金支出进行估算。结果:假设降脂通络软胶囊进入药品目录乙类后,在现有市场份额基础上,平均每年分别替代血脂康胶囊4%、降脂通脉胶囊4%、蒲参胶囊10%的市场份额,预计2021~2025年在治疗原发性高脂血症中,因降脂通络软胶囊纳入药品目录乙类而增加的医保基金支出分别为-176万元、-1732万元、-3297万元、-4871万元、-6457万元,增加的医保基金支出分别占原发性高脂血症治疗中的医保基金支出的-0.16%,-1.55%,-2.97%,-4.43%和-5.92%。敏感性分析显示预算影响分析结果较稳定,当降脂通络软胶囊价格上调至约36.66元/盒(规格:50 mg×36粒/盒)时,可增加医保基金支出,但在此价格下2022年及以后仍可节约医保基金。结论:在本研究假定参数下,若降脂通络软胶囊进入药品目录乙类,平均每年分别替代血脂康胶囊4%、降脂通脉胶囊4%、蒲参胶囊10%的市场份额,以当前中标价格作为2021~2025年药品价格,将能够减少医保基金的支出,并且随着降脂通络软胶囊市场份额的增大,将会节约更多的医保基金。Objective:To evaluate the possible impact of Jiangzhi Tongluo soft capsules on the expenditure of medical insurance fund when it is included in Drug Catalogue of National Basic Medical Insurance,Employment Injury Insurance and Maternity Insurance(hereinafter referred to as the“drug catalogue”).Methods:Based on the budget impact analysis guidelines published by the International Association for Pharmacoeconomics and Results Research,the budget impact analysis model of Jiangzhi Tongluo soft capsules in the treatment of primary hyperlipidemia was established by Excel software.The simulation time range of the model was set to 5 years(2021-2025).The possible impact of Jiangzhi Tongluo soft capsules on the expenditure of medical insurance fund was evaluated.Results:Assuming that Jiangzhi Tongluo soft capsules are included in the directory,on the basis of the existing market share,it could respectively replace the market share of Xuezhikang capsules 4%,Jiangzhi Tongmai capsules 4%and Pushen capsules 10%.It was estimated that from 2021 to 2025,in the treatment of primary hyperlipidemia,the increase in medical insurance fund expenditures due to the inclusion of Jiangzhi Tongluo soft capsules in the drug catalogue class B will be-1.76 million yuan,-17.32 million yuan,-32.97 million yuan,-48.71 million yuan,and-64.57 million yuan.The increased medical insurance fund expenditures will account for-0.16%,-1.55%,-2.97%,-4.43%and-5.92%of the medical insurance fund expenditures in the treatment of primary hyperlipidemia.Sensitivity analysis showed that the results of budget impact analysis were relatively stable.When the price of Jiangzhi Tongluo soft capsules was increased to about 36.66 yuan/box(specification:50 mg×36 capsules/box),the medical insurance fund expenditure could be increased,but the medical insurance fund could still be saved at this price in 2022 and beyond.Conclusion:Under the assumed parameters of this study,if Jiangzhi Tongluo soft capsules are included in the drug catalogue,it will respectively replace t

关 键 词：降脂通络软胶囊 原发性高脂血症 预算影响分析 药物经济学 

分 类 号：F407.7[经济管理—产业经济]